Skip to content

Patient Registry to Study the Tined Lead Used With the InterStim System For Urinary Control

Patient Registry to Study the Tined Lead Used With the InterStim System For Urinary Control

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00225966
Enrollment
153
Registered
2005-09-26
Start date
2004-08-31
Completion date
2007-10-31
Last updated
2013-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urge Incontinence, Urinary Retention

Keywords

Urinary urgency-frequency

Brief summary

The purpose of this study is assess the long-term safety and effectiveness of the InterStim tined lead using a minimally invasive approach.

Interventions

DEVICEDevice Medtronic InterStim Tined Leads Models 3889 and 3093

Sponsors

MedtronicNeuro
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum

Inclusion criteria

* Signed and dated informed consent * 16 years of age or greater * Willing and able to complete voiding diaries and questionnaires at various time points during the study * Located geographically near the physician, or willing and able to travel to the physician's site as necessary for all required visits * Failed or is not a candidate for more conservative treatment

Exclusion criteria

* Severe or uncontrolled diabetes; or diabetes with peripheral nerve involvement * Pregnancy or planned pregnancy * Concomitant medical conditions which would limit the success of the procedure such as: pelvic pain with uncertain etiology, active degenerative disc disease, spinal cord injury less than six months old, bleeding complications, or a cerebrovascular accident (CVA) less than six months old. * Anatomical limitations that would prevent successful placement of an electrode * Neurological diseases such as multiple sclerosis, clinically significant peripheral neuropathy or complete spinal cord injury (e.g., paraplegia) * Subject characteristics indicating a poor understanding of the study or poor compliance with the study protocol (e.g. subjects with psychological and/or emotional problems, subjects unable to adequately operate equipment) * Subjects with knowledge of planned magnetic resonance imaging (MRI), diathermy, microwave, high output ultrasonics, ultrasound scanning, or radiofrequency (RF) energy * Mechanical obstruction such as benign prostatic hypertrophy, cancer, or urethral stricture * Symptomatic urinary tract infection (UTI). Upon completion of therapy for UTI, or if the subject is receiving prophylaxis for UTI, subjects can be considered for test stimulation or the full system implant (whichever is applicable) if symptom free for one month prior to the procedure. * Subjects with other implantable neurostimulators, pacemakers, or defibrillators * Primary stress incontinence or mixed incontinence where the stress component overrides the urge component * Active participation in another clinical study

Design outcomes

Primary

MeasureTime frame
Incidence of adverse events requiring surgical intervention
Incidence of lead migration

Secondary

MeasureTime frame
Incidence of infection

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026